cp wire

CP Wire Articles

MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today presented the positive... read more

Fri, 04/13/18 - 12:42 pm
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis

Gilead Sciences, Inc. (Nasdaq: GILD) today presented data from a proof-of-concept study of investigational combination therapies for patients with advanced fibrosis due to nonalcoholic... read more

Fri, 04/13/18 - 12:10 pm
Allergan Announces Launch of the TrueTear Intranasal Neurostimulation Device


Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced the official launch of TrueTear, the first and only FDA-cleared device developed to temporarily increase... read more

Fri, 04/13/18 - 09:47 am
Galapagos Announces ISABELA Ph III Study in Idiopathic Pulmonary Fibrosis



  • GLPG1690 has orphan drug status in US and Europe
  • Ph II results showed disease stabilization over 12 week period
  • ISABELA intended to support NDA and MAA in... read more
Thu, 04/12/18 - 08:26 pm
Wistar Researchers Find Combination Therapy Effective for NRAS Mutant and Therapy Resistant Melanoma

Wistar researchers have identified a novel therapeutic vulnerability in NRAS mutant melanoma and an effective strategy to address it, using a combination of two clinically relevant inhibitors,... read more

Thu, 04/12/18 - 11:56 am

Pages